The KD Pharma Group has acquired a 51% stake in Trigal Pharma

BIOGGIO, SWITZERLAND – October 4, 2021 – The KD Pharma Group has acquired a 51% stake in Trigal Pharma, a company specialized in clinical research, development and marketing of medical cannabinoids, such as Cannabidiol (CBD) in a highly-purified form.

“Trigal has successfully and profitably grown by being a first mover in the API market for cannabidiol (“CBD”), which is a natural fit with the KD Pharma Group,” said Oscar Groet, CEO of the KD Pharma Group.  “KD Pharma is a technology leader in lipid-based APIs, so adding cannabinoid leadership from Trigal into the KD Pharma family will help accelerate growth for both companies in this dynamic area.”

“We are pleased to form this strategic partnership with KD Pharma,” said Dr. Eberhard Pirich MD and CEO of Trigal Pharma, “because we have a shared vision that the market will demand more highly purified cannabinoids made under pharma GMP conditions in the future.”

The KD Pharma Group manufactures extracts and cannabinoid isolates at its facilities in Germany using its broad portfolio of lipid technologies, including novel technology for the extraction, concentration and isolation of cannabinoids. Trigal Pharma manufactures and distributes CBD API through the magistral preparations channel in Austria and Germany, including a partnership with a large Austrian pharmacy. The KD Pharma Group’s goal is to build the market leader in medical cannabinoids, a market that is largely untapped and has significant growth potential due to the pipeline of research in conditions ranging from neurological and psychotic disorders, treatment of substance use disorders and addiction, chronic pain conditions to cardiovascular disease and cancer.

Trigal Pharma will form an advisory board comprising of directors appointed by both companies immediately following the close of the transaction.  Other terms of the transaction were not disclosed.

About Trigal Pharma

Trigal Pharma is a pharmaceutical company, founded 2011 with more than 15 years of practical experience in clinical research and development, regulatory affairs and marketing of medical cannabinoids, particularly Cannabidiol. Since 2015 Cannabidiol capsules of different strengths as well as liquids for magisterial preparations have been developed in a very successful R&D cooperation with an Austrian pharmacy. Since more than four years in accordance with GMP standards CBD capsules have been produced for clinical trials in Australia and Europe, as well. In summary Trigal Pharma understands its role as a service company bringing scientific and marketing expertise in different sectors to globally operating manufacturers and producers of natural CBD and other cannabinoids.

About the KD Pharma Group SA

The KD Pharma Group is a CDMO that develops products in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer of API for Omega-3 pharmaceuticals and has built a similar market-leading position in Omega-3 nutraceuticals, formulation and encapsulation services, with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit www.kdpharmagroup.com to learn more.

Pressemitteilungen

capiton portfolio company Dec Group is proud to announce the acquisition of UK-Stoke-on-Trent based AWL, a specialist for the design, manufacturing and supply of continuous processing technologies and systems. Over the past decade, AWL has been at the forefront of continuous processing in the chemical, food and pharmaceutical industries by offering solutions from laboratory evaluation […]

capiton portfolio company Wundex is pleased to announce the acquisition of ELLIPSA, a wound care specialist with headquarters in Regensburg (Bavaria) and a second center of operations in Munich. In addition to the provision of wound care services and the wholesale supply of medical products, ELLIPSA has developed a proprietary digital education and training platform […]

capiton portfolio company Cedes is proud to announce the acquisition of the Vitector portfolio from Fraba, securing a leading position in the industrial door sensor market. As a global leader in elevator sensors, Cedes successfully applied its technology expertise and power of innovation to gain a foothold in the industrial door market, providing ultra-reliable safeguarding […]

Asyril SA, headquartered in Villaz-St-Pierre in Switzerland with subsidiaries in the US and Japan, is a market and technology leader in the flexible part feeder market. Its products are being used globally in assembly lines, facilitating process automation for a variety of industries.   Asyril’s product portfolio covers flexible feeding systems based on a patented […]

AlphaPet Ventures has started to implement its international expansion strategy with the acquisition of Arden Grange, a leading UK brand in the premium dog food segment. Family-run Arden Grange pioneered the category of species-appropriate dog food in the UK more than 25 years ago. Customers appreciate especially the high quality of the products, which aim […]

We are delighted to announce the successful acquisition of Stuga Machinery by our portfolio company Stürtz Group.   Stuga Machinery Limited, a market leading manufacturer of PVC sawing and machining centres to the UK and Ireland windows and doors industry, has been acquired by Stürtz Group. All of Stuga’s Directors and staff are continuing with […]

We are delighted to announce that our portfolio company EVP Group is combining forces with Vitafy Brands. Founded in Munich in 2014, Vitafy Brands has grown to be a leading consumer health D2C online platform for its own brands focusing on the development and offering of functional Consumer Health OTC products for health focused customers. […]

capiton acquires a majority stake in the Betonbau Group alongside its experienced management team, Mr. Volker Ernst and Mr. Thomas Sachers, from the SCHWENK Group in a carve-out transaction. Betonbau Group, headquartered in Waghäusel, Germany, was established in 1963. The name “Betonbau” goes back to its foundations when the company focused on the production of […]

capiton successfully closes fund VI at €504 million Largest fund in the company’s history Approximately €260 million, including co-investment, already deployed in seven portfolio companies Fund to continue successful deployment in capiton’s focus sectors Pharmaceuticals, Medical Technology, Industrial Technology and Responsible Consumption   Berlin, 24 November 2021 – capiton AG (“capiton”), a leading owner-managed private […]

capiton acquires a stake in Solvis, a sustainable heating pioneer, backing the members of the management team which remain significant shareholders in the company. Solvis is headquartered in Braunschweig, Germany. The company was founded in 1982 and retains its operations in a factory which has been inaugurated as the first zero-emission-facility in Germany in 2002. […]

capiton acquires the majority stake in Kutterer Mauer AG, backing one of the founders, Mr. Mauer in continuing the growth story of the company. Mr. Mauer as well as other management members invest alongside capiton. Kutterer Mauer AG is a globally operating manufacturer of caps and closure solutions with >450 employees. The Group designs and […]

capiton has successfully closed a new top-up single-asset fund for its fast-growing portfolio company KD Pharma Group („KD Pharma“). This top-up fund will provide KD Pharma with the equity financing for a number of additional strategic investments, in particular add-on acquisitions as well as organic growth initiatives to transfer KD Pharma‘s unique technology and service […]